Skip to main content

Table 1 Assessment of risk of bias in included studies

From: Efficacy and safety of proton beam therapy for rhabdomyosarcoma: a systematic review and meta-analysis

References

Criterion

a

b

c

d

e

f

g

h

i

j

USA

          

Ladra et al. [13]

Yes

Yes

Yes

Yes

No

Yes

Yes

Yes

No

Yes

Indelicato et al. [14]

Yes

Yes

Yes

Yes

No

Yes

Yes

Yes

No

Yes

Ludmir et al. [15]

Yes

Yes

Yes

Yes

No

Yes

Yes

Yes

No

Yes

Bradley et al. [16]

Yes

Yes

Yes

Yes

No

Yes

Yes

Yes

No

Yes

Indelicato et al. [17]

Yes

Yes

Yes

Yes

No

Yes

Yes

Yes

No

Yes

Buszek et al. [18]

Yes

Yes

Yes

Yes

No

Yes

Yes

Yes

No

Yes

Parekh et al. [19]

Yes

Yes

Yes

Yes

No

Yes

Yes

Yes

No

Yes

Japan

          

Mizumoto et al. [20]

Yes

Yes

Yes

Yes

No

Yes

Yes

Yes

No

Yes

Suzuki et al. [21]

Yes

Yes

Yes

Yes

No

Yes

Yes

Yes

No

Yes

Switzerland

          

Leiser et al. [22]

Yes

Yes

Yes

Yes

No

Yes

Yes

Yes

No

Yes

Weber et al. [23]

Yes

Yes

Yes

Yes

No

Yes

Yes

Yes

No

Yes

  1. (a) Were there clear criteria for inclusion in the case series?; (b) Was the condition measured in a standard, reliable way for all participants included in the case series?; (c) Were valid methods used for identification of the condition for all participants included in the case series?; (d) Did the case series have consecutive inclusion of participants?; (e) Did the case series have complete inclusion of participants?; (f) Was there clear reporting of the demographics of the participants in the study?; (g) Was there clear reporting of clinical information of the participants?; (h) Were the outcomes or follow-up results of cases clearly reported?; (i) Was there clear reporting of the presenting sites’/clinics’ demographic information?; (j) Was statistical analysis appropriate?
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us